search
Back to results

PREPL in Health and Disease (PHD)

Primary Purpose

Hypotonia-Cystinuria Syndrome, Muscle Hypotonia, Healthy Volunteers

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Blood draw
muscle biopsy
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hypotonia-Cystinuria Syndrome

Eligibility Criteria

undefined - 40 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • According to group
  • Control group: children seen at a postinfectious consultation

Exclusion Criteria:

  • Control group: symptoms overlapping with PREPL deficiency, genetic or syndromic disease, atypically developing children
  • other groups: contraindication for blood draw
  • group with muscle biopsy: contra-indication for muscle biopsy

Sites / Locations

  • UZLeuven

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Control Blood

Primary PREPL deficiency Blood

Prader Willi syndrome Blood

Primary PREPL deficiency like Blood

Control muscle

Prader-Willli syndrome muscle

Arm Description

Patients on routine postinfectious control, blood draw

Patients with primary PREPL deficiency, blood draw

Patients with Prader-Willi syndrome, blood draw

Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw

Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw

Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw

Outcomes

Primary Outcome Measures

PREPL activity (ng active PREPL/g protein) normal values in blood
normal values for PREPL activity
PREPL activity in patients with Prader Willi syndrome compared to activity in normal controls
Comparison of PREPL activity in blood and muscle between above mentioned groups
PREPL activity in patients with primary PREPL deficiency compared to activity in normal controls
Comparison of PREPL activity in blood between above mentioned groups

Secondary Outcome Measures

PREPL activity in patients with muscle weakness/obesity/growth hormone deficiency compared to activity in normal controls
exploratory evaluation

Full Information

First Posted
October 1, 2014
Last Updated
October 13, 2014
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT02263781
Brief Title
PREPL in Health and Disease
Acronym
PHD
Official Title
PREPL in Health and Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Unknown status
Study Start Date
October 2014 (undefined)
Primary Completion Date
January 2015 (Anticipated)
Study Completion Date
January 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
KU Leuven

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of PREPL activity in healthy controls and known or possible PREPL deficient patients
Detailed Description
PREPL is defective in hypotonia cystinuria syndrome and in isolated PREPL deficiency. The investigators have constructed a blood test to evaluate PREPL activity in patients with possible PREPL deficiency. The study will determine normal values for age (0-18) for PREPL activity in blood. Also, patients with a clinical phenotype that overlaps with PREPL deficiency (including patients with known primary PREPL deficiency and Prader-Willi syndrome) will be evaluated for PREPL activity in blood. A last part of the study will involve muscle biopsies during elective anesthesia/surgery for other reasons. There will be 2 groups: patients without signs of PREPL deficiency undergoing surgery (controls) and patients with Prader-Willi syndrome undergoing anesthesia or surgery (patients). The control group will be age-matched to the hypotonia group. In the muscle biopsies, PREPL activity and expression will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotonia-Cystinuria Syndrome, Muscle Hypotonia, Healthy Volunteers, Dwarfism, Growth Hormone Deficiency, Obesity, Prader-Willi Syndrome

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
125 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Blood
Arm Type
Experimental
Arm Description
Patients on routine postinfectious control, blood draw
Arm Title
Primary PREPL deficiency Blood
Arm Type
Experimental
Arm Description
Patients with primary PREPL deficiency, blood draw
Arm Title
Prader Willi syndrome Blood
Arm Type
Experimental
Arm Description
Patients with Prader-Willi syndrome, blood draw
Arm Title
Primary PREPL deficiency like Blood
Arm Type
Experimental
Arm Description
Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
Arm Title
Control muscle
Arm Type
Experimental
Arm Description
Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
Arm Title
Prader-Willli syndrome muscle
Arm Type
Experimental
Arm Description
Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
Intervention Type
Procedure
Intervention Name(s)
Blood draw
Intervention Description
Blood draw
Intervention Type
Procedure
Intervention Name(s)
muscle biopsy
Intervention Description
Muscle biopsy during planned anesthesia/surgery
Primary Outcome Measure Information:
Title
PREPL activity (ng active PREPL/g protein) normal values in blood
Description
normal values for PREPL activity
Time Frame
3 months
Title
PREPL activity in patients with Prader Willi syndrome compared to activity in normal controls
Description
Comparison of PREPL activity in blood and muscle between above mentioned groups
Time Frame
3 months
Title
PREPL activity in patients with primary PREPL deficiency compared to activity in normal controls
Description
Comparison of PREPL activity in blood between above mentioned groups
Time Frame
3 months
Secondary Outcome Measure Information:
Title
PREPL activity in patients with muscle weakness/obesity/growth hormone deficiency compared to activity in normal controls
Description
exploratory evaluation
Time Frame
3 months

10. Eligibility

Sex
All
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: According to group Control group: children seen at a postinfectious consultation Exclusion Criteria: Control group: symptoms overlapping with PREPL deficiency, genetic or syndromic disease, atypically developing children other groups: contraindication for blood draw group with muscle biopsy: contra-indication for muscle biopsy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luc Régal, MD
Phone
003216343820
Email
luc.regal@uzleuven.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luc Régal, MD
Organizational Affiliation
KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
UZLeuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luc Régal, MD
Phone
003216343820
Email
Luc.regal@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Luc Régal, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
24610330
Citation
Regal L, Shen XM, Selcen D, Verhille C, Meulemans S, Creemers JW, Engel AG. PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology. 2014 Apr 8;82(14):1254-60. doi: 10.1212/WNL.0000000000000295. Epub 2014 Mar 7.
Results Reference
background
PubMed Identifier
16385448
Citation
Jaeken J, Martens K, Francois I, Eyskens F, Lecointre C, Derua R, Meulemans S, Slootstra JW, Waelkens E, de Zegher F, Creemers JW, Matthijs G. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. Am J Hum Genet. 2006 Jan;78(1):38-51. doi: 10.1086/498852. Epub 2005 Nov 23.
Results Reference
background

Learn more about this trial

PREPL in Health and Disease

We'll reach out to this number within 24 hrs